Health and wellness company doTERRA reported on Monday the appointment of Russell J. Osguthorpe, MD as its new chief medical officer as well as vice president of its medical and scientific initiatives.
The company said Dr Osguthorpe replaces its founding executive Dr David Hill, who remains as chairman of the Scientific Advisory Committee and Medical Executive Committee as well as continues his global mission to educate about essential oils. Dr Osguthorpe reports to Dave Stirling and Dr Hill.
As part of the medical team, Dr Osguthorpe, a medical executive trained in Pediatric Infectious Diseases, will lead the company's healthcare and research teams. His direct reports include Dr Brannick Riggs, MD, Nicole Stevens MS and Cody Beaumont, PhD.
Most recently, Dr Osguthorpe was employed with Intermountain Healthcare as well as a paediatric medical director and paediatric department chair of a tertiary care hospital.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial